Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2933001 | 0.79 | MC4R (0.54) | MC4R | |
| SCHEMBL27961380 | 0.72 | HRH3 (0.45) | BACE1HRH3 | |
| SCHEMBL2933683 | 0.71 | ACP1 (0.39) | BACE1MC4RSIGMAR1 | |
| SCHEMBL17678283 | 0.71 | HRH3 (0.43) | BACE1HRH3SIGMAR1 | |
| SCHEMBL17527302 | 0.71 | HRH3 (0.43) | BACE1HRH3 | |
| SCHEMBL13921696 | 0.70 | MC4R (0.65) | MC4R | |
| SCHEMBL11713412 | 0.69 | HRH3 (0.56) | BACE1HRH3 | |
| SCHEMBL2930807 | 0.68 | ACP1 (0.49) | HRH3MC4R | |
| SCHEMBL3874659 | 0.67 | HRH3 (0.53) | BACE1HRH3 | |
| SCHEMBL1779245 | 0.67 | HRH3 (0.46) | BACE1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316201-A1 | NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2012-12-13 | — | — | US | disclosed |
| US-8288395-B2 | Pyrimido-benzimidzole derivatives and the use thereof in the form of agonists or antagonists of melanocortin receptors | IPSEN PHARMA S.A.S. (FR) | 2012-10-16 | — | — | US | disclosed |
| US-8227485-B2 | Benzimidazole and imidazopyridine derivatives and use thereof as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-07-24 | — | — | US | disclosed |
| US-20100256135-A1 | PYRIMIDO-BENZIMIDZOLE DERIVATIVES AND THE USE THEREOF IN THE FORM OF AGONISTS OR ANTAGONISTS OF MELANOCORTIN RECEPTORS | IPSEN PHARMA S.A.S. (FR) | 2010-10-07 | — | — | US | disclosed |
| EP-1692114-B1 | NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | IPSEN PHARMA (FR) | 2010-09-22 | — | — | EP | disclosed |
| US-7763725-B2 | used for treating metabolic, nervous sytsem and skin disorders,inflammatory diseases, obesity, cachexia, erectile dysfunction, neuropathic pain, or as antidepressants, anxiolytic and anticarcinogenic agents | IPSEN PHARMA S.A.S. (FR) | 2010-07-27 | — | — | US | disclosed |
| US-20090209531-A1 | Pyrimido-Benzimidazole Derivatives and the Use Thereof in the Form of Agonists and Antagonists of Melanocortin Receptors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2009-08-20 | — | — | US | disclosed |
| EP-1768985-B1 | PYRIMIDO-BENZIMIDAZOLE DERIVATIVES AND THE USE THEREOF IN THE FORM OF AGONISTS OR ANTAGONISTS OF MELANOCORTIN RECEPTORS | SOD CONSEILS RECH APPLIC (FR) | 2008-01-23 | — | — | EP | disclosed |
| US-20060281784-A1 | Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2006-12-14 | — | — | US | disclosed |
| EP-1692114-A1 | NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005056533-A1 | NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316201-A1 | NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | MC4R, MC5R, MC1R | BACE1 4691/4885HRH3 147/4885MC4R 1/4885 |
| US-20060281784-A1 | Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament | MC4R, MC5R, MC1R | BACE1 4548/4885HRH3 149/4885MC4R 1/4885 |
| US-20100256135-A1 | PYRIMIDO-BENZIMIDZOLE DERIVATIVES AND THE USE THEREOF IN THE FORM OF AGONISTS OR ANTAGONISTS OF MELANOCORTIN RECEPTORS | MC4R, MC5R, MC1R | BACE1 4122/4885HRH3 302/4885MC4R 1/4885 |
| US-20090209531-A1 | Pyrimido-Benzimidazole Derivatives and the Use Thereof in the Form of Agonists and Antagonists of Melanocortin Receptors | MC4R, MC5R, MC1R | BACE1 4143/4885HRH3 308/4885MC4R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.